Compare Stocks: IVVD, CADL, DRUG, and EVO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.01	$9.21	$4.35 ▼ $11.36	$733.43M	-0.51	1.29 million shs	1.12 million shs
DRUG Bright Minds Biosciences	$73.26	$71.18	$31.80 ▼ $123.75	$712.82M	-5.27	248,361 shs	212,596 shs
EVO Evotec	$1.91	$2.56	$1.90 ▼ $4.27	$679.49M	1.92	65,529 shs	34,104 shs
IVVD Invivyd	$0.54	$0.87	$0.48 ▼ $3.07	$157.62M	0.71	3.40 million shs	2.30 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	+4.71%	+1.83%	+54.71%	+59.14%
DRUG Bright Minds Biosciences	0.00%	+2.71%	+8.37%	-15.75%	+117.84%
EVO Evotec	0.00%	-1.55%	-34.14%	-38.19%	-52.49%
IVVD Invivyd	0.00%	-12.50%	-40.14%	-64.80%	-26.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.01	$9.21	$4.35 ▼ $11.36	$733.43M	-0.51	1.29 million shs	1.12 million shs
DRUG Bright Minds Biosciences	$73.26	$71.18	$31.80 ▼ $123.75	$712.82M	-5.27	248,361 shs	212,596 shs
EVO Evotec	$1.91	$2.56	$1.90 ▼ $4.27	$679.49M	1.92	65,529 shs	34,104 shs
IVVD Invivyd	$0.54	$0.87	$0.48 ▼ $3.07	$157.62M	0.71	3.40 million shs	2.30 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	+4.71%	+1.83%	+54.71%	+59.14%
DRUG Bright Minds Biosciences	0.00%	+2.71%	+8.37%	-15.75%	+117.84%
EVO Evotec	0.00%	-1.55%	-34.14%	-38.19%	-52.49%
IVVD Invivyd	0.00%	-12.50%	-40.14%	-64.80%	-26.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.60	Moderate Buy	$18.57	85.53% Upside
DRUG Bright Minds Biosciences	3.14	Buy	$143.83	96.33% Upside
EVO Evotec	2.20	Hold	$3.00	57.07% Upside
IVVD Invivyd	2.33	Hold	$8.00	1,395.33% Upside

Current Analyst Ratings Breakdown

Latest IVVD, CADL, DRUG, and EVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
7/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/21/2026	EVO Evotec	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/21/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	CADL Candel Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	EVO Evotec	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/15/2026	EVO Evotec	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $4.00
7/15/2026	EVO Evotec	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/13/2026	CADL Candel Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$22.00
7/7/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/15/2026	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
EVO Evotec	$745.04M	0.91	N/A	N/A	$2.59 per share	0.74
IVVD Invivyd	$53.43M	2.95	N/A	N/A	$1.04 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$38.18M	-$0.98	N/A	N/A	N/A	N/A	-60.42%	-41.33%	8/13/2026 (Estimated)
DRUG Bright Minds Biosciences	-$8.74M	-$2.44	N/A	N/A	N/A	N/A	-20.58%	-20.25%	8/13/2026 (Estimated)
EVO Evotec	-$117.12M	N/A	N/A	N/A	N/A	-26.20%	-24.93%	-11.35%	8/13/2026 (Estimated)
IVVD Invivyd	-$52.49M	-$0.31	N/A	N/A	N/A	-138.90%	-53.48%	-41.56%	8/13/2026 (Estimated)

Latest IVVD, CADL, DRUG, and EVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.22	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2831	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	EVO Evotec	-$0.0470	N/A	N/A	N/A	$177.24 million	N/A
8/13/2026	Q2 2026	IVVD Invivyd	-$0.15	N/A	N/A	N/A	$14.40 million	N/A
5/20/2026	Q2 2026	DRUG Bright Minds Biosciences	-$0.8633	-$0.80	+$0.0633	-$0.80	N/A	N/A
5/14/2026	Q1 2026	CADL Candel Therapeutics	-$0.2958	-$0.14	+$0.1558	-$0.14	N/A	N/A
5/14/2026	Q1 2026	IVVD Invivyd	-$0.08	-$0.13	-$0.05	-$0.13	$18.04 million	$13.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
EVO Evotec	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.34	28.05	28.05
DRUG Bright Minds Biosciences	N/A	81.47	81.47
EVO Evotec	0.43	1.68	1.60
IVVD Invivyd	N/A	6.47	6.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
DRUG Bright Minds Biosciences	40.52%
EVO Evotec	5.81%
IVVD Invivyd	70.36%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
DRUG Bright Minds Biosciences	42.66%
EVO Evotec	1.00%
IVVD Invivyd	12.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	73.27 million	62.79 million	Optionable
DRUG Bright Minds Biosciences	N/A	9.73 million	5.58 million	Not Optionable
EVO Evotec	4,553	355.76 million	N/A	Not Optionable
IVVD Invivyd	100	294.61 million	258.52 million	Optionable

IVVD, CADL, DRUG, and EVO Headlines

Recent News About These Companies

Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts

2 hours ago | marketbeat.com

Invivyd (NASDAQ:IVVD) Shares Up 7.1% - Should You Buy?

July 31 at 3:23 AM | americanbankingnews.com

Invivyd (NASDAQ:IVVD) Stock Price Up 7.1% - Here's What Happened

July 31 at 3:19 AM | marketbeat.com

Invivyd (NASDAQ:IVVD) and Zai Lab (NASDAQ:ZLAB) Financial Analysis

July 31 at 2:28 AM | americanbankingnews.com

Invivyd Receives Nasdaq Notice for Bid Price Deficiency

July 24, 2026 | tipranks.com

Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Recommendation of "Hold" from Brokerages

July 9, 2026 | marketbeat.com

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

July 6, 2026 | markets.businessinsider.com

IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval

July 6, 2026 | finance.yahoo.com

Invivyd, Inc. Announces FDA Notice of Termination for PEMGARDA EUA Following HHS COVID-19 Emergency Declaration Wind-Down

July 6, 2026 | quiverquant.comQ

Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

July 6, 2026 | globenewswire.com

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

June 29, 2026 | globenewswire.com

Invivyd Posts Strong Q1 Results, Advances VYD2311 Programs

June 25, 2026 | theglobeandmail.com

Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311

June 19, 2026 | finance.yahoo.com

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

June 16, 2026 | globenewswire.com

Invivyd Inc (IVVD) Reports Clinical Progress. Stock Expected to Explode

June 12, 2026 | insidermonkey.com

Invivyd doses first participants in Phase 3 COVID-19 trial

June 9, 2026 | proactiveinvestors.com

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to ...

June 9, 2026 | markets.businessinsider.com

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration

June 9, 2026 | globenewswire.com

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2026 | globenewswire.com

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

June 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IVVD, CADL, DRUG, and EVO Company Descriptions

Candel Therapeutics NASDAQ:CADL

$10.01 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$9.91 -0.10 (-0.96%)

As of 07/31/2026 07:52 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Bright Minds Biosciences NASDAQ:DRUG

$73.26 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$73.10 -0.16 (-0.22%)

As of 07/31/2026 07:34 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Evotec NASDAQ:EVO

$1.91 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.93 +0.02 (+1.05%)

As of 07/31/2026 07:34 PM Eastern

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Invivyd NASDAQ:IVVD

$0.54 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.54 +0.00 (+0.56%)

As of 07/31/2026 07:56 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVVD, CADL, DRUG, and EVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVVD, CADL, DRUG, and EVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVVD, CADL, DRUG, and EVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IVVD, CADL, DRUG, and EVO Company Descriptions

Candel Therapeutics NASDAQ:CADL

Bright Minds Biosciences NASDAQ:DRUG

Evotec NASDAQ:EVO

Invivyd NASDAQ:IVVD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVVD, CADL, DRUG, and EVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVVD, CADL, DRUG, and EVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVVD, CADL, DRUG, and EVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IVVD, CADL, DRUG, and EVO Company Descriptions

Candel Therapeutics NASDAQ:CADL

Bright Minds Biosciences NASDAQ:DRUG

Evotec NASDAQ:EVO

Invivyd NASDAQ:IVVD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools